# Golden Patient 4 - Chronic Kidney Disease Patient

## Patient Overview

- **Story Arc:** Diabetic nephropathy → Progressive CKD (Stage 3→4→5) → Dialysis preparation
  > "Patient t204 is a 35-year-old male with diabetic kidney disease who progresses from CKD Stage 3 to Stage 5 requiring dialysis preparation over 18 months. His data demonstrates nephrology-specific queries: trending renal function, electrolytes, anemia management, and dialysis access procedures."

---

## Clinical Story

### Background (Diagnosed age 25 in 2015):

- **Type 2 Diabetes** diagnosed at age 25 (early onset, strong family history)
- **Hypertension** developed at age 27
- Poor glycemic control for 8 years (HbA1c 8.5-10.2%)
- Developed **microalbuminuria** at age 30 (early diabetic nephropathy)

### Current Presentation (Age 35, January 2025):

Patient presents with fatigue, decreased appetite, mild ankle swelling. Labs reveal:

- **Creatinine: 2.1 mg/dL** (elevated, was 1.4 six months ago)
- **eGFR: 38 mL/min** (CKD Stage 3b - moderate to severe reduction)
- **HbA1c: 8.8%** (poorly controlled diabetes)
- **Albumin: 2.8 g/dL** (low, indicating protein malnutrition)
- **Potassium: 5.4 mEq/L** (borderline high)
- **Phosphorus: 5.2 mg/dL** (elevated)
- **Hemoglobin: 10.2 g/dL** (anemia of CKD)
- **Blood Pressure: 158/94** (poorly controlled hypertension)

**Diagnosis:** CKD Stage 3b due to diabetic nephropathy

---

## Timeline: Disease Progression

### Phase 1: Initial CKD Diagnosis (Encounter 1 - January 2025)

**What happened:** Patient presents with fatigue and declining kidney function

**Key Findings:**

- 5 **Conditions** diagnosed:

  - Chronic kidney disease stage 3b (eGFR 38)
  - Diabetic nephropathy (cause of CKD)
  - Anemia due to chronic kidney disease
  - Hypertension (poorly controlled)
  - Type 2 diabetes mellitus (poorly controlled)

- 2 **Allergies** documented:

  - Allergy to NSAIDs (ibuprofen, naproxen - nephrotoxic)
  - Allergy to sulfa drugs

- **Comprehensive Labs:**

  - Renal panel: Creatinine 2.1, BUN 38, eGFR 38
  - CMP: Electrolytes with elevated K+ 5.4, elevated phosphorus 5.2
  - CBC: Hemoglobin 10.2 (anemia)
  - Lipid panel: Dyslipidemia
  - HbA1c: 8.8%
  - Urine albumin/creatinine ratio: 450 mg/g (severe proteinuria)

- **4 Medications started:**

  - Insulin glargine 20 units (improved diabetes control)
  - Amlodipine 10mg (blood pressure, kidney-safe)
  - Atorvastatin 40mg (cardiovascular protection)
  - Ferrous sulfate 325mg (treat anemia)

- **2 Imaging studies:**
  - Renal ultrasound (assess kidney size/structure)
  - Echocardiogram (assess cardiac function)

**Care Plan:** CKD management plan initiated

---

### Phase 2: CKD Progression to Stage 4 (Encounter 2 - April 2025, 3 months later)

**What happened:** Follow-up shows worsening kidney function despite treatment

**Key Findings:**

- **Condition updated:** CKD progressed to **Stage 4** (eGFR 25 - severe reduction)

- **Worsening Labs:**

  - Creatinine: 2.8 mg/dL (↑ from 2.1)
  - eGFR: 25 mL/min (↓ from 38)
  - Hemoglobin: 9.1 g/dL (worsening anemia)
  - Potassium: 5.7 mEq/L (elevated, needs monitoring)
  - Phosphorus: 5.8 mg/dL (elevated)
  - Calcium: 8.2 mg/dL (low)
  - Parathyroid hormone (PTH): 180 pg/mL (elevated - secondary hyperparathyroidism)
  - HbA1c: 8.2% (improved but still not at goal)

- **3 New Medications added:**

  - Erythropoietin (EPO) injections 4000 units (treat anemia)
  - Sodium bicarbonate 650mg (correct metabolic acidosis)
  - Sevelamer 800mg (phosphate binder)

- **Procedures:**
  - Nephrology consultation
  - Dialysis education session (preparation for future)

**Clinical Note:** Patient counseled about disease progression and likely need for dialysis within 6-12 months

---

### Phase 3: Approaching End-Stage (Encounter 3 - July 2025, 3 months later)

**What happened:** Further decline, now CKD Stage 5, dialysis planning begins

**Key Findings:**

- **Condition updated:** CKD progressed to **Stage 5** (eGFR 12 - kidney failure)

- **Critical Labs:**

  - Creatinine: 4.8 mg/dL (↑ from 2.8)
  - eGFR: 12 mL/min (↓ from 25)
  - Hemoglobin: 8.5 g/dL (severe anemia despite EPO)
  - Potassium: 6.1 mEq/L (dangerously high)
  - Bicarbonate: 16 mEq/L (metabolic acidosis)
  - Phosphorus: 6.5 mg/dL (very elevated)
  - PTH: 285 pg/mL (worsening bone disease)

- **Imaging:**

  - Vascular mapping ultrasound (plan AV fistula for hemodialysis)
  - Chest X-ray (pre-procedure clearance)

- **New Care Plan:** Dialysis preparation care plan initiated

- **Medication adjustment:**
  - EPO dose increased to 6000 units
  - Calcitriol 0.25mcg added (treat bone disease)
  - Sodium polystyrene sulfonate (Kayexalate) added PRN (manage high potassium)

**Clinical Decision:** Plan for AV fistula creation for future hemodialysis

---

### Phase 4: Dialysis Access Creation (Encounter 4 - August 2025, 1 month later)

**What happened:** Surgical creation of arteriovenous fistula for hemodialysis access

**Key Activities:**

- **Procedure:** Left radiocephalic AV fistula creation (forearm)

  - Surgery duration: 90-120 minutes
  - Outpatient surgery center
  - Post-op vascular ultrasound to confirm patency

- **Pre-op Labs:**

  - CBC: Ensure adequate hemoglobin before surgery
  - Coagulation studies (PT/INR): Normal clotting
  - CMP: Electrolytes stable

- **Post-op Care:**
  - Fistula education provided
  - Follow-up scheduled for fistula maturation check

**Clinical Note:** Fistula needs 6-8 weeks to mature before use for dialysis

---

### Phase 5: Pre-Dialysis Monitoring (Encounter 5 - October 2025, 2 months later)

**What happened:** Close monitoring as patient approaches dialysis initiation

**Key Findings:**

- **Labs continue to worsen:**

  - Creatinine: 6.2 mg/dL
  - eGFR: 9 mL/min
  - Uremic symptoms developing (nausea, fatigue, confusion)

- **Imaging:**

  - Fistula ultrasound: Good flow, maturing well
  - Chest X-ray: Early pulmonary edema (fluid overload)

- **Procedures:**
  - Dialysis catheter placement (temporary, in case fistula not ready)
  - Pre-dialysis assessment

**Clinical Decision:** Plan to start hemodialysis within 2 weeks

---

### Phase 6: Hemodialysis Initiation (Encounter 6 - October 2025, 2 weeks later)

**What happened:** First hemodialysis treatment

**Key Activities:**

- **Procedure:** First hemodialysis session

  - Duration: 4 hours
  - Via temporary dialysis catheter (fistula still maturing)
  - Dialysis center

- **Labs post-dialysis:**

  - Creatinine: 4.1 mg/dL (↓ from 6.2 - improved after dialysis)
  - Potassium: 4.2 mEq/L (normalized)
  - Hemoglobin: 9.2 g/dL (stable on EPO)

- **New Care Plan:** Chronic hemodialysis care plan
  - Schedule: Monday/Wednesday/Friday, 4 hours each
  - Continue EPO, phosphate binders, vitamin D

**Clinical Note:** Patient tolerating dialysis well, plan transition to fistula in 2-4 weeks

---

### Phase 7: Ongoing Dialysis (Encounters 7-9, Monthly follow-ups)

**November 2025 (Encounter 7):**

- Switched to AV fistula for dialysis (catheter removed)
- Monthly labs: Stable on dialysis
- Dialysis adequacy test (Kt/V): Good clearance
- Continue chronic medications

**December 2025 (Encounter 8):**

- Routine dialysis follow-up
- HbA1c: 7.2% (improved with insulin adjustments)
- Hemoglobin: 10.5 g/dL (improved on EPO)
- Discussed kidney transplant evaluation

**January 2026 (Encounter 9):**

- Transplant workup initiated
- Comprehensive labs for transplant evaluation
- Imaging: CT chest/abdomen/pelvis for surgical planning
- Cardiac stress test (pre-transplant cardiac clearance)

---

## Testing Value for TRAIS LLM

### Unique Query Types This Patient Enables:

1. **Trending Renal Function:**

   - "Show me the creatinine trend"
   - "How has the GFR changed over time?"
   - "When did the patient progress to Stage 5 CKD?"

2. **Electrolyte Management:**

   - "What is the most recent potassium?"
   - "Show me the phosphorus values over time"
   - "Is the patient's bicarbonate low?"

3. **Anemia Management:**

   - "Show me hemoglobin trend"
   - "Is the patient on EPO?"
   - "What dose of erythropoietin is the patient receiving?"

4. **Dialysis-Specific Queries:**

   - "When did the patient start dialysis?"
   - "Does the patient have a fistula or catheter?"
   - "Show me dialysis adequacy results"

5. **Procedure Queries:**

   - "What procedures has the patient had?"
   - "When was the AV fistula created?"
   - "Has the patient had any vascular imaging?"

6. **CKD Complication Monitoring:**

   - "What is the PTH level?" (bone disease)
   - "Is the patient on phosphate binders?"
   - "Show me calcium and vitamin D levels"

7. **Disease Progression Analysis:**
   - "How fast did kidney function decline?"
   - "Compare creatinine at diagnosis vs now"
   - "What stage of CKD is the patient in?"

---

## Resource Summary

### Total Resources: ~115

- **Patient:** 1
- **Conditions:** 5-7 (CKD stages update, comorbidities)
- **AllergyIntolerance:** 2 (NSAIDs, Sulfa drugs)
- **CarePlan:** 3 (CKD management, Dialysis prep, Chronic dialysis)
- **Encounters:** 9 (Initial diagnosis, 6 follow-ups, surgery, dialysis initiation)
- **DiagnosticReport:** 28 (9 comprehensive metabolic panels, 9 CBCs, 4 Renal panels, 3 Lipid panels, 2 PTH, 1 Kt/V)
- **Observation:** 35+ (separate observations for trending labs: creatinine, eGFR, plus vitals)
- **ImagingStudy:** 8 (2 Renal ultrasounds, 2 Fistula ultrasounds, 2 Chest X-rays, 1 Echo, 1 CT)
- **Procedure:** 8 (2 Nephrology consults, AV fistula creation, Dialysis catheter placement, 3 Hemodialysis sessions, Fistula removal)
- **MedicationRequest:** 12-15 (Multiple medications with dose adjustments)

---

## Key Testing Strengths

1. **Younger Patient:** Age 35 vs 55+ in other patients - tests age-related queries
2. **Progressive Disease:** Clear stage progression (3b→4→5) - tests temporal analysis
3. **Nephrology Focus:** Unique specialty with specific labs (creatinine, GFR, PTH, Kt/V)
4. **Procedure-Heavy:** Multiple procedures (fistula, catheter, dialysis) - tests procedure queries
5. **Frequent Monitoring:** 9 encounters over 12 months - tests "recent" vs "all" queries
6. **Electrolyte Complexity:** Multiple electrolyte abnormalities - tests specific value queries
7. **Treatment Trajectory:** Medical management → Surgical intervention → Dialysis - tests multi-phase care

---

## Clinical Narrative Flow

**Act 1 (Jan 2025):** Discovery - Young man with poorly controlled diabetes learns his kidneys are failing

**Act 2 (Apr-Jul 2025):** Decline - Watching kidney function deteriorate despite treatment, Stage 3→4→5

**Act 3 (Aug-Oct 2025):** Preparation - Creating dialysis access, preparing for life-sustaining treatment

**Act 4 (Oct 2025+):** New Reality - Starting chronic hemodialysis, learning to live with kidney failure

**Epilogue:** Hope - Beginning transplant evaluation for potential kidney transplant

---

This patient complements the existing golden patients by:

- Adding a **younger adult** demographic
- Focusing on **nephrology/dialysis** (unique specialty)
- Demonstrating **progressive disease with clear stages**
- Testing **procedure-heavy workflows**
- Providing **frequent lab monitoring** scenarios
- Enabling **trending analysis** queries critical for TRAIS testing
